Clinical Trial

Therapy Duration Study in Metastatic Melanoma

Study Description

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Intermittent PD-1 inhibitor therapy

Drug - Continuous PD-1 inhibitor therapy

Additional Information

Official Study Title

A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Clinical Trial ID

NCT02821013

ParticipAid ID

RdGAKa